ROCO
6578
Market cap37mUSD
Oct 08, Last price
16.65TWD
1D
2.78%
1Q
1.52%
Jan 2017
-38.67%
IPO
-44.33%
Name
Dabomb Protein Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaBomb-P (Aqua) and DaBomb-P (Livestock), alongside specific antibiotic alternative solutions like DBT-100 HT and DBT-100 LS. The company also manufactures pet care products, featuring LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. Founded in 2001 and headquartered in Tainan, Taiwan, the firm adopted its current name, DaBomb Protein Biotech Corp., in October 2023, having previously operated as DaBomb Protein Corp.
Key people
Wei-Chen Chen
Chairman of the Board, General Manager · since 2025
Jianquan Chen
Director · since 2025
Qizhen Chen
Director · since 2025
Yu-Fen Liu
Chairman of the Board, General Manager · since 2014
Huawei Huang
Independent Director · since 2017
Lubing Xu
Independent Director · since 2023
Yongfu Zhang
Independent Director · since 2023
Huizheng Zhou
Independent Director · since 2025
Shumei Zhu
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||